<2>Novo Nordisk’s Obesity Drug Falls Short in Trial, Shares Plunge
<3>The Danish pharmaceutical company Novo Nordisk has seen its shares plummet after its experimental obesity drug, semaglutide, failed to outperform a rival treatment in a clinical trial. The disappointing results have sparked concerns about the company’s ability to compete in the increasingly crowded market for weight loss medications.
<4>According to a recent statement from Novo Nordisk, the company’s shares fell by as much as 9.5% in early trading, wiping out over $20 billion in market value. This decline is a significant setback for the company, which had high hopes for semaglutide as a potential blockbuster treatment for obesity.
<5>The clinical trial in question, known as the STEP-7 trial, compared semaglutide to a rival treatment called tirzepatide, which is developed by Eli Lilly and Company. The results showed that tirzepatide was more effective in reducing body weight and improving glycemic control in patients with type 2 diabetes.
<6>Novo Nordisk’s semaglutide, on the other hand, failed to demonstrate a significant advantage over tirzepatide in terms of weight loss and glyc